BDD Pharma Raises £2M for Drug Formulation and Trials
BDD Pharma, an Edinburgh, Scotland, UK-based Integrated drug formulation and clinical trials company, recently announced that it has raised £2M in funding. The funding round was led by existing investors, including angel syndicate Archangels, Scottish Enterprise, and new investor British Business Bank. With these funds, the company plans to accelerate its business expansion efforts.
Under the leadership of CEO Dr Carol Thomson, BDD Pharma specializes in drug development, providing formulation development expertise, on-demand GMP manufacture, and specialist clinical trial services to pharmaceutical companies.
Their unique approach combines drug delivery expertise with clinical capabilities, allowing them to accelerate product development pipelines, enable life cycle management, and create new value-added products.
One of BDD Pharma's key assets is its patented oral drug delivery technology called OralogiK™. This innovative technology allows for the timed release of active pharmaceutical ingredients tailored to specific modified-release needs. It can support sustained, delayed, multiple pulse, and site-targeted release, opening the door to the development of novel complex formulations and life cycle management opportunities.
They've invested in BDD Pharma
Get to know these Healthtech investors
Click here for a full list of 6,481+ startup investors in the UK